A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
According to In vitro studies, ciclesonide showed good antiviral activity against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for
the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical
trial to evaluate the antiviral effect on the reduction of viral load in patients with
COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could
eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.